/

Sociétés

RI

Non vérifié

RIBOMIC Inc.

Ce que nous écrivons

BiotechnologieIndustrieIndustrie pharmaceutiqueSantéVitrines/Shopping

3 communiqués de presse

Voir tous les communiqués de presse

07/10/2025

Santé

Vitrines/Shopping

Biotechnologie

Enfance

Médecine - Divers

Industrie pharmaceutique

Industrie

RIBOMIC Announces Positive Phase 2 Cohort 2 Results for Umedaptanib Pegol in Achondroplasia, Demonstrating an Increase in the Annualized Growth Rate of up to +5.0 cm/year with Biweekly Administration in Children Aged 5 Years and Older

Source

Émetteur

1.00

0

05/11/2024

Industrie

Santé

Vitrines/Shopping

Biotechnologie

Enfance

Médecine - Divers

Industrie pharmaceutique

RIBOMIC Announces Positive Interim Results from Phase IIa Trial of umedaptanib pegol in Achondroplasia Demonstrating Increase in Annualized Growth Rate of up to +4.6 cm/year in Children 5 Years of Age and Older in the Low Dose Cohort

Source

Émetteur

1.00

0

03/08/2024

Santé

Vitrines/Shopping

Biotechnologie

Enfance

Médecine - Divers

Industrie pharmaceutique

Industrie

RIBOMIC Announces Completion of Patient Enrollment in Early Phase II Study of umedaptanib pegol for Achondroplasia and Initiation of Dosing in Cohort 2 of Early Phase II Clinical Study

Source

Émetteur

1.00

0

Followers

0

Compatibilité

0